Logo

GSK Expands its License Agreement with Zymework to Develop and Commercialize Bi-Specific Antibodies

Share this

GSK Expands its License Agreement with Zymework to Develop and Commercialize Bi-Specific Antibodies

Shots:

  • Zymework to receive preclinical- development & commercial milestone payments and royalties on WW sales. GSK to get an option to develop and commercialize bi-specific candidates for multiple indications including infectious diseases utilizing Zymeworks’ heavy-light chain pairing technology of Azymetric platform
  • In 2016- the companies collaborated to develop & commercialize up to six bispecific antibodies utilizing Zymeworks’s Azymetric platform
  • Zymeworks’s Azymetric platform allows the transformation of monospecific Ab to bispecific Ab- enabling it to bind with two different targets- thus reducing toxicities and drug resistance        

Ref: Business Wire | Image: GSK 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions